NCT00131430已完成2 期
An 18-Month Study to Assess the Safety, Tolerability, and Efficacy of MK0364 in Obese Patients
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 500
- 主要终点
- After 24 weeks, body weight, safety, and tolerability
研究概览
简要总结
A study to determine the safety and efficacy of an investigational drug in patients with obesity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Obese patients with a body mass index between 30kg/m2 and 43 kg/m2, inclusive (BMI between 27 kg/m2 and 43kg/m2, inclusive for those with obesity-related comorbidities including hypertension, dyslipidemia and sleep apnea).
排除标准
- •Patients with serious or unstable current or past medical conditions.
结局指标
主要结局
After 24 weeks, body weight, safety, and tolerability
时间窗: After 24 weeks
次要结局
- After 80 weeks, body weight(After 80 weeks)
研究者
相似试验
已完成
1 期
12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis PatientsMultiple SclerosisNCT00616733Daiichi Sankyo25
终止
3 期
An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)Type 2 Diabetes MellitusNCT00130806Merck Sharp & Dohme LLC600
终止
2 期
A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal TransplantationKidney TransplantationNCT06365437ITB-Med LLC33
已完成
2 期
A Dose Escalation Study in de Novo Renal TransplantationKidney TransplantationNCT04311632ITB-Med LLC13
已完成
1 期
A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 DiabetesHealthy VolunteersDiabetes Mellitus, Type 1NCT03965013Novo Nordisk A/S78